Iatrogenic Effects of COX-2 Inhibitors in the US Population

@article{Vaithianathan2009IatrogenicEO,
  title={Iatrogenic Effects of COX-2 Inhibitors in the US Population},
  author={Rhema Vaithianathan and Peter M. Hockey and Thomas J. Moore and D. Bates},
  journal={Drug Safety},
  year={2009},
  volume={32},
  pages={335-343}
}
AbstractBackground: Selective cyclo-oxygenase 2 inhibitors (‘coxibs’) have been demonstrated to increase cardiovascular risk, but the cumulative burden of adverse effects in the US population is uncertain. Objective: To quantify cardiovascular and gastrointestinal (GI) haemorrhage disease burden from coxibs and traditional ‘non-selective’ non-steroidal anti-inflammatory drugs (t-NSAIDs) in the US population. Design, setting and participants: Adult respondents from the 1999–2003 Medical… Expand
Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.
TLDR
NSAID use is not associated with an increased risk of incident myocardial infarction and HF but is associated with a reduction in all-cause mortality in Australian veterans. Expand
Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications.
  • S. Harirforoosh, Waheed Asghar, F. Jamali
  • Medicine
  • Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
  • 2013
TLDR
The GI toxicity of the NSAIDs is discussed, lower but still therapeutics doses of some NSAIDs may be cardioprotective and their renal and CV adverse effects are assessed. Expand
Review on Effects of NSAID`S on Different Systems
Non steroidal anti-inflammatory drugs (NSAIDs) are amongst the most commonly prescribed medication. Some are available over the counter and likely to be abused. The gastrointestinal (GI), renal andExpand
Selective inhibition of cyclooxygenase-2: risks and benefits.
TLDR
The mechanisms underlying the cardiovascular effects are discussed, pointing out the advantages and disadvantages of the selective or nonselective COX inhibitors. Expand
Inibição seletiva da ciclo-oxigenase-2: riscos e benefícios
TLDR
The mechanisms underlying the cardiovascular effects are discussed, pointing out the advantages and disadvantages of the selective or nonselective COX inhibitors. Expand
Cyclooxygenase Inhibition and P 2 Y 12 Antagonism
Aspirin is perhaps the most cost-effective therapy in medicine. Its evolution as a mainstay of cardioprotection illustrates interlocking contributions of industry and academia, the importance ofExpand
Emotion recollected in tranquility: lessons learned from the COX-2 saga.
TLDR
Evidence from human pharmacology and genetics, genetically manipulated rodents, and other animal models and randomized trials indicates that this is consequent to suppression of COX-2-dependent cardioprotective prostagladins, particularly prostacyclin. Expand
Prostanoids and NSAIDs in Cardiovascular Biology and Disease
TLDR
Newer understanding of the pathophysiology of atherosclerosis and the pharmacology of prostanoids promises potential resolution of current problems resulting from the hazards of available prostanoid-altering drugs. Expand
“Safe and Effective When Used As Directed”: The Case of Chronic Use of Opioid Analgesics
TLDR
A prudent treatment approach consistent with the available evidence would be to reserve chronic opioid therapy for serious pain-related problems for which the effectiveness of opioids has been demonstrated and for patients whose use as directed is assured through close monitoring. Expand
Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis
TLDR
EPA-FFA has chemopreventative efficacy in FAP, to a degree similar to that previously observed with selective cyclo-oxygenase-2 inhibitors, and holds promise as a colorectal cancer Chemoprevention agent with a favourable safety profile. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 19 REFERENCES
Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs and the Risk of Ischemic Stroke: A Nested Case-Control Study
TLDR
It is suggested that COX-2 selective NSAIDs differ in their potential to cause ischemic cerebrovascular events and an increased risk of isChemic stroke may be influenced by additional pharmacological properties of individual COx-2 inhibitors. Expand
Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
TLDR
No consistent evidence was found of enhanced safety against gastrointestinal events with any of the new cyclo-oxygenase-2 inhibitors compared with non-selective non-steroidal anti-inflammatory drugs. Expand
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
TLDR
Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk, and cardiovascular mortality was similar in the two groups. Expand
COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense.
TLDR
Within months of rofecoxib’s approval in May 1999, the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial reported a 50% reduction in serious gastrointestinal outcomes, but a 5-fold increase in thromboembolic cardiovascular events (primarily acute myocardial infarction [MI]) among patients treated with 50 mg/d of roFECoxib compared with 1000 mg/D of naproxen. Expand
Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction
TLDR
Selective COX-2 inhibitors in all dosages and nonselective NSAIDs in high dosages increase mortality in patients with previous MI and should therefore be used with particular caution in these patients. Expand
Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs
TLDR
After attempting to correct for channelling bias, coxib exposure, but not meloxicam exposure, was associated with a significantly lower risk of gastrointestinal haemorrhage than older non-specific NSAIDs exposure. Expand
Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population
TLDR
The semi-selective NSAIDs had the highest odds ratio for upper GI events even after adjusting for various potential confounders, and the GI safety of the COX-2 selective NSAIDs was not demonstrated as definitively superior to non-selectives. Expand
Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
TLDR
Current and new users of rofecoxib and celecoxib had an elevated risk estimate for hospitalization for MI compared with nonusers of any category of nonaspirin NSAIDs, which indicates the need for further examination of the cardiovascular safety of all non aspirinNSAIDs. Expand
Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study
TLDR
Rofecoxib use increases the risk of serious coronary heart disease compared with celecoxib use, and naproxen use does not protect against serious coronaryHeart disease. Expand
Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis
TLDR
Evidence of differential cardiovascular risk as a function of celecoxib dose regimen and baseline cardiovascular risk is observed and may help guide treatment decisions for patients who derive clinical benefit from selective cyclooxygenase-2 inhibition. Expand
...
1
2
...